In a 68-year-old patient discharged three days ago after acute pancreatitis with hyperbilirubinemia and elevated transaminases, who has type 2 diabetes, hypertension, and hyperlipidemia and is taking atorvastatin 10 mg, hydrochlorothiazide 12.5 mg, fenofibrate 145 mg, pantoprazole 40 mg, lisinopril 10 mg, and tirzepatide (Mounjaro) 15 mg, what should the primary care physician do at the one‑week post‑discharge visit?

Immediate Post-Discharge Management After Acute Pancreatitis

You must immediately discontinue both Mounjaro (tirzepatide) and fenofibrate, as these medications are directly implicated in causing acute pancreatitis and represent an unacceptable risk of recurrence that could be fatal.

Critical Medication Review and Discontinuation

Stop immediately:

• Mounjaro 15 mg - The FDA label explicitly warns about pancreatitis risk, stating patients should "stop using MOUNJARO and call your healthcare provider right away if you have severe pain in your stomach area" 1. Recent case reports document tirzepatide-induced acute pancreatitis with strong temporal correlation between drug initiation and symptom onset 2. The drug increases risk of gallbladder/biliary disease in patients with diabetes 3.

• Fenofibrate 145 mg - This fibrate is a known trigger for acute pancreatitis, particularly in patients with recent pancreatic inflammation 4, 5. While useful for hypertriglyceridemia, continuing it post-pancreatitis poses recurrence risk.

Potentially problematic medications requiring evaluation:

• Atorvastatin 10 mg - Case reports document statin-induced pancreatitis 6. However, given the patient's hyperlipidemia and cardiovascular risk profile, the benefit likely outweighs risk at this low dose. Monitor closely but may continue cautiously.

• HCTZ 12.5 mg - Documented cause of recurrent acute pancreatitis 7. Consider switching to an alternative antihypertensive (e.g., increase lisinopril dose or add amlodipine) to eliminate this risk factor.

Essential Clinical Assessment Today

Symptom evaluation - specifically ask about:

• Persistent or recurrent epigastric/upper abdominal pain
• Nausea, vomiting, or inability to tolerate oral intake
• Fever (suggesting infected necrosis or complications)
• Jaundice or dark urine (biliary obstruction)
• Changes in stool color (clay-colored suggests biliary issues)

Physical examination - focus on:

• Epigastric tenderness or mass (pseudocyst formation)
• Jaundice (scleral icterus)
• Signs of dehydration
• Abdominal distension or peritoneal signs

Laboratory Monitoring Required

Order today:

• Lipase and amylase - Should be trending down; persistent elevation suggests ongoing inflammation or complications
• Liver function tests (AST, ALT, alkaline phosphatase, bilirubin) - Monitor resolution of hyperbilirubinemia and transaminitis
• Complete metabolic panel - Assess kidney function (dehydration risk), calcium (hypercalcemia as cause), glucose control
• Fasting lipid panel including triglycerides - Critical to identify hypertriglyceridemia as etiology (levels >1000 mg/dL cause pancreatitis) 4, 5
• HbA1c - Assess diabetes control now that Mounjaro is discontinued

Determine Etiology to Prevent Recurrence

The 2019 WSES guidelines emphasize that "the etiology of AP should be determined, to project the need of definitive treatment and to avoid recurrence" 8.

Based on hospital findings (hyperbilirubinemia, elevated transaminases):

• Most likely: Biliary/gallstone pancreatitis - Early elevation of transaminases and bilirubin strongly suggests gallstone etiology 9
• Review hospital imaging - Was ultrasound or MRCP performed? Were gallstones identified?
• If gallstones present: Urgent surgical referral for cholecystectomy within 2 weeks of discharge (ideally should have been done during hospitalization for mild pancreatitis) 10, 11

Alternative etiologies to exclude:

• Hypertriglyceridemia - Check fasting triglycerides today; levels >1000 mg/dL are causative 4
• Drug-induced - Mounjaro, fenofibrate, HCTZ, and atorvastatin all implicated 2, 6, 7
• Alcohol use - Document alcohol intake in units/week 9

Imaging Follow-Up

If not done during hospitalization or if severe pancreatitis:

• The optimal timing for contrast-enhanced CT is 72-96 hours after symptom onset to assess for necrosis 8
• If patient had severe pancreatitis (organ failure, extensive necrosis), ensure CT was performed 3-10 days post-admission 9
• If etiology unclear, consider abdominal ultrasound today to evaluate for gallstones (repeat if initial was negative) 9

Diabetes Management Without Mounjaro

Immediate plan:

• Resume or initiate basal insulin - Patient will need alternative glucose control. For HbA1c 7-9%, add basal insulin or intensify oral agents 12
• Continue metformin if tolerated and no contraindications
• Consider adding: SGLT2 inhibitor (empagliflozin, dapagliflozin) for cardiovascular/renal protection, or DPP-4 inhibitor (though these also carry pancreatitis warnings) 13
• Monitor glucose closely - Patient may experience hyperglycemia rebound after stopping Mounjaro

Definitive Treatment Planning

For biliary pancreatitis:

• Cholecystectomy must occur within 2 weeks of discharge - UK guidelines strongly emphasize this timing to prevent potentially fatal recurrent pancreatitis 10, 9
• Refer to general surgery urgently today
• If patient is unfit for surgery, endoscopic sphincterotomy is alternative 10

For hypertriglyceridemia-induced pancreatitis:

• Target triglycerides <500 mg/dL (ideally <150 mg/dL)
• Do NOT restart fenofibrate - use omega-3 fatty acids (4g daily), strict low-fat diet, optimize diabetes control
• In acute recurrence, insulin therapy rapidly lowers triglycerides 4

Patient Education and Safety Planning

Instruct patient to return immediately for:

• Severe abdominal pain (pancreatitis recurrence)
• Persistent nausea/vomiting or inability to eat/drink
• Fever >38.5°C (101.3°F)
• Jaundice or dark urine
• Severe hypoglycemia symptoms after stopping Mounjaro

Dietary counseling:

• Low-fat diet (<30g fat/day initially) to reduce pancreatic stimulation
• Small, frequent meals
• Avoid alcohol completely
• Adequate hydration

Common Pitfalls to Avoid

1. Do not restart Mounjaro or fenofibrate - The temporal relationship to pancreatitis makes these medications unacceptably dangerous 1, 2

2. Do not delay cholecystectomy if gallstones present - Recurrent biliary pancreatitis can be severe and fatal; definitive treatment should occur within 2 weeks 10

3. Do not assume pancreatitis has fully resolved - Verify with repeat lipase and clinical assessment

4. Do not overlook hypertriglyceridemia - This is a treatable cause that requires aggressive management distinct from standard hyperlipidemia 4, 5

5. Do not continue HCTZ without consideration - Switch to alternative antihypertensive to eliminate this risk factor 7